

# Transcatheter aortic valve implantation in a very young patient with failed bioprothesis as a bridge to transplantation procedure



<u>Luca Katalin Kuthi<sup>1</sup></u>, Anikó Ilona Nagy <sup>1</sup>, Levente Molnár <sup>1</sup>, Krisztina Heltai <sup>1</sup>, Endre Zima <sup>1</sup>, Zoltán Szeberin <sup>1</sup>, Béla Merkely <sup>1</sup>

<sup>1</sup>Semmelweis University Heart and Vascular Center, Budapest, Hungary


#### Introduction

In patients with congenital aortic valve disease repeat aortic valve surgery is necessary in about one third of the cases (1). Transcatheter aortic valve replacement has been reported as a viable alternative of redo surgery in patients with degenerated bioprosthetic valves (valve in valve procedure) (2).

### Case presentation

We report the case of a 24-year-old female, with history of surgical closure of a ventricular septal defect in her preadolescence, followed by replacement of a stenotic bicuspid aortic valve at the age of 19. With respect to her desire of having children, the patient chose to receive a bioprosthesis. 4 years later, follow up echocardiography revealed signs of advanced prosthesis degeneration. However, due to the high risk of a second redo operation and because the patient was clinically asymptomatic, her treating physicians decided not to intervene.

22 months later the patient was admitted in our center for acute decompensated heart failure. At admission, echocardiography showed severely depressed ejection fraction with low flow high gradient severe stenosis of the degenerated bioprosthesis.






Fig. 1 and 2: The pre TAVI echocardiography of the patient

Multidisciplinary heart team considered the patient unsuitable for open-heart surgery, due to the history of multiple cardiac surgeries with sternotomy and cardiac arrest, therefore we decided to perform a valve in valve TAVI procedure, potentially as a bridge to transplantation solution.

A 23 mm Evolute R (Medtronic, Minneapolis, MN) was deployed in general anesthesia from a. iliaca access (femoral access was not possible due to the patients unusually gracile vasculature).







Fig. 3 and 4: The Medtronic Evolute R valve

Echo values	Pre TAVI	3 months post TAVI	12 months post TAVI	24 months post TAVI
EF	33 %	54 %	51 %	60%
Peak/Mean gradient	78/50 Hgmm	42/24 Hgmm	43/29 Hgmm	32/16 Hgmm
Vmax	4.7 m/s	2.3 m/s	3.3 m/s	2.8 m/s

Immediately after implantation, the patient showed marked improvement in her functional status. At three months follow-up, she was in NYHA I. Nearly full recovery of left ventricular systolic function was documented along with normalization of right sided pressures.






Fig. 5 and 6: The 12 months post TAVI echocardiography of the patient

## Discussion

Surgical aortic valve replacement remains the gold standard for the treatment of aortic stenosis. At present, the indication of TAVI is limited to patients with high- or prohibitive risk for operation usually with advanced age; nonetheless, there is a trend towards its application in intermediate risk patients and younger generations.

In the presented case TAVI was successfully applied in a very young patient with congenital heart disease in order to minimize cumulative morbidity resulting from repeated open-heart surgery and to facilitate later cardiac transplantation. A repositionable self-expanding valve was chosen because accurate device positioning is often challenging in patients with homograft, and particularly in this case, the preceding septal operation resulted in specific anatomy. The major concern around the use of TAVI in younger patients is its durability, however, the medium-term results of TAVI are excellent (3, 4), suggesting that in selected young patients, in whom the individual advantages of TAVI outweigh the expected excellent long-term results of conventional surgical AVR, this treatment approach might provide a much safer and clinically efficient solution (5-8).

## References

- 1. Karamlou T, Jang K, Williams WG, Caldarone CA, Van Arsdell G, Coles JG, McCrindle BW. Outcomes and associated risk factors for aortic valve replacement in 160 children: a competing-risks analysis. Circulation. 2005 Nov 29;112(22):3462-3469.

  2. Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures F, Hengstenberg C, Moat NE, Bekeredjian R, Napodano M, Testa L, Lefevre T, Guetta V, Nissen H, Hernandez JM, Roy D, Teles RC, Segev A, Dumonteil N, Fiorina C, Gotzmann M, Tchetche D, Abdel-Wahab M, De Marco F, Baumbach A, Laborde JC, Kornowski R. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation. 2012 Nov 6;126(19):2335-2344.
- 3. Cribier A, Durand E, Eltchaninoff H. Patient selection for TAVI in 2014: is it justified to treat low- or intermediate-risk patients? The cardiologist's view. EuroIntervention. 2014 Sep;10 Suppl U:U16-21.
- 4. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, Webb JG, Mack MJ, Douglas PS, Thourani VH, Babaliaros VC, Herrmann HC, Szeto WY, Pichard AD, Williams MR, Fontana GP, Miller DC, Anderson WN, Akin JJ, Davidson MJ, Smith CR, investigators Pt. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Jun 20;385(9986):2485-2491.

  5. Ahmad K, Terkelsen CJ, Terp KA, Mathiassen ON, Norgaard BL, Andersen HR, Poulsen SH. Transcatheter aortic valve
- implantation in a young heart transplant recipient crossing the traditional boundaries. J Thorac Dis. 2016 Aug;8(8):E711-714.

  6. Attia R, Visagan R, Nowell J, Chadalavada S, Thomas M, Bapat V. Transapical transcatheter aortic valve implantation in a complex aortic surgical patient: A case involving the youngest valve-in-valve implantation with a 29 mm transcather valve. Exp Clin Cardiol. 2012 Winter;17(4):251-253.
- 7. Diez JG, Schechter M, Dougherty KG, Preventza O, Coselli JS. Transcatheter Aortic Valve-in-Valve Replacement Instead of a 4th Sternotomy in a 21-Year-Old Woman with Aortic Homograft Failure. Tex Heart Inst J. 2016 Aug;43(4):334-337.

  8. Saji M, Hoyt WJ, Jr., Ailawadi G, Mulloy DP, Ghanta RK, Ragosta M, Scott Lim D. Transcatheter Aortic Valve Replacement

in a Young Adult Patient with a Failed Homograft. Pediatr Cardiol. 2016 Jun;37(5):986-988.